NCT05367505进行中（未招募）不适用
Prospective Pilot Study With a Titanium Fusion Implant in Combination With Trans-iliac Screws for Insufficiency Fractures of the Pelvis
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 50
- 试验地点
- 5
- 主要终点
- Proportion of patients who regain their pre-fracture mobility as measured by the FMS by the time of hospital discharge
研究概览
简要总结
Many approaches to the surgical treatment of OF-P have been tried, but no one method has stood out as particularly successful. The placement of three implants, including implants that could minimise motion in the sacroiliac joint through early fixation and long-term fusion of the sacroiliac joint, can prevent micromotion in the fracture and thereby improve the clinical outcome of OF-Ps.
The iFuse-3D implant was shown to be safe and effective for chronic sacroiliac pain in non-osteoporotic patients.
The primary aim is to assess the proportion of patients operated on using iFuse-3D in conjunction with transiliac-transsacral screws who regain pre-fracture mobility by the time of hospital discharge.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Legal capacity, capacity to inform
- •Presence of a written declaration of consent by the patient
- •Age: ≥ 60 years
- •Acute or subacute (less than 2 months) posterior pelvic girdle pain associated with low energy trauma or occurring spontaneously
- •Diagnosis confirmed by CT and/or MRI
- •The fracture corresponds to types OF3 and OF4 of the OF Pelvis classification.
- •Prior to the fracture, there was free, non-wheelchair mobility (Functional Mobility Score of 2 or higher)
排除标准
- •Diagnosed uncontrolled psychiatric illness (e.g. dementia, schizophrenia, major depression, personality disorder) that could affect study participation or reporting of findings
- •History of pelvic fracture within one year with evidence of failure of fracture to heal or internal fixation of the pelvic ring of any type
- •Patients unable to ambulate before the fracture
- •Patient has had lumbar instrumentation of more than two vertebrae and/or instrumentation of S1 in the past
- •Additional fractures that limit mobility
- •OF-P associated with benign or malignant tumours of the pelvis
- •Abnormal neurological condition that could affect study participation
- •An unusual clinical condition associated with a high risk of not being able to follow up (e.g. COPD, severe heart failure, Parkinson's disease, autoimmune diseases)
- •Any pelvic condition or anatomical feature that makes surgery impracticable
- •Known allergy to titanium or titanium alloys
- •Known opioid abuse for chronic pain syndromes
- •Participation in other interventional trials
- •Lack of surgical capability
- •Persons in a dependent/employee relationship with the sponsor or investigator
- •Placement in an institution due to court or administrative order.
研究组 & 干预措施
iFuse-3D
Experimental
Titanium fusion implant in combination with trans-iliac screws
干预措施: iFuse-3D implant (Device)
结局指标
主要结局
Proportion of patients who regain their pre-fracture mobility as measured by the FMS by the time of hospital discharge
时间窗: Time 8 days (discharge) after surgery
The proportion is shown with frequencies and corresponding percentages.
次要结局
- Proportion of patients who achieve pre-fracture mobility at six months.(Time six months after surgery)
- Proportion of patients who achieved an FMS ≥ 2 at three months.(Time three months after surgery)
- Opioid consumption and osteoporosis medication in the last six months.(Time six months after surgery)
- Proportion of patients who achieve pre-fracture mobility at three months.(Time three months after surgery)
- Proportion of patients who achieve pre-fracture mobility at 12 months.(Time 12 months after surgery)
- Proportion of patients who achieved an FMS ≥ 2 within six weeks.(Time six weeks after surgery)
- Proportion of patients who achieve pre-fracture mobility within six weeks.(Time six weeks after surgery)
- Proportion of patients who achieved an FMS ≥ 2 at six months.(Time six months after surgery)
- Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) at three months.(Time three months after surgery)
- Timed up and go test after three months.(Time three months after surgery)
- Timed up and go test after six months.(Time six months after surgery)
- Proportion of patients who achieved an FMS ≥ 2 (= walking with assistive devices) at discharge.(Time 8 days (discharge) after surgery)
- Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) at 12 months.(Time 12 months after surgery)
- Timed up and go test after 12 months.(Time 12 months after surgery)
- Proportion of screws or iFuse fractures.(Time within 12 months)
- Proportion of infections.(Time within 12 months)
- Timed up and go test after six weeks.(Time six weeks after surgery)
- Proportion of patients who achieved an FMS ≥ 2 at 12 months.(Time 12 months after surgery)
- Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) within six weeks.(Time six weeks after surgery)
- Change in posterior pelvic girdle pain at rest and when attempting to walk measured by a NRS (0-10) at six months.(Time six months after surgery)
- Opioid consumption and osteoporosis medication in the last six weeks.(Time six weeks after surgery)
- Opioid consumption and osteoporosis medication in the last three months.(Time three months after surgery)
- Opioid consumption and osteoporosis medication in the last 12 months.(Time 12 months after surgery)
- Change in quality of life measured by the EuroQol-5D-3L after six weeks.(Time six weeks after surgery)
- Change in quality of life measured by the EuroQol-5D-3L after six months.(Time six months after surgery)
- Change in quality of life measured by the EuroQol-5D-3L after 12 months.(Time 12 months after surgery)
- Proportion of radiological signs of loosening.(Time within 12 months)
- Change in quality of life measured by the EuroQol-5D-3L after three months.(Time three months after surgery)
- Proportion of screw sintering.(Time within 12 months)
- Proportion of sintering/migration of the iFuse implant.(Time within 12 months)
研究者
研究点 (5)
Loading locations...
相似试验
尚未招募
1 期
Hyperbaric Oxygen Therapy for Perianal Fistulizing Crohn's Disease Not Responsive or Intolerant to Conventional Care: HYPNOTIC Pilot StudyInflammatory Bowel Disease (IBD)Crohn DiseaseNCT06109961University of British Columbia54
已完成
2 期
Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal FusionDegenerative Disc DiseaseNCT02205138Bone Therapeutics S.A38
已完成
不适用
A Prospective Pilot Study of the OP-1 Putty in Uninstrumented Posterolateral FusionsDegenerative Lumbar SpondylolisthesisNCT00679107Olympus Biotech Corporation48
招募中
不适用
Comparison of a Novel Transperineal Targeted Fusion Biopsy System to Conventional Transrectal Targeted Fusion BiopsyProstate CancerNCT03936127Dr. Nicola Schieda360
终止
不适用
Investigator Initiated Trial to Further Evaluate the Safety and Efficacy of Trans-perineal Focal Laser Ablation of Localized Prostate Cancer Using High Frequency Micro-ultrasound ImagingLow-risk or Favorable Intermediate Risk Prostate Cancer Who Are on an Active Surveillance RegimenProstate CancerNCT05826470Genesis Research LLC4